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is a relative contraindication because of the risks to the patient
from potentially hazardous interactions between the MRI and the
pacemaker system. Chest scans (ie, cardiac magnetic resonance
scans) are of particular importance and higher risk. The previously
Food and Drug Administration-approved magnetic resonance con-
ditional system includes positioning restrictions, limiting the
powerful utility of MRI.
OBJECTIVE To confirm the safety and effectiveness of a pacemaker
system designed for safe whole body MRI without MRI scan
positioning restrictions.
METHODS Primary eligibility criteria included standard dual-
chamber pacing indications. Patients (n ¼ 263) were randomized
in a 2:1 ratio to undergo 16 chest and head scans at 1.5 T between 9
and 12 weeks postimplant (n ¼ 177) or to not undergo MRI (n ¼
86) post-implant. Evaluation of the pacemaker system occurred
immediately before, during (monitoring), and after MRI, 1-week
post-MRI, and 1-month post-MRI, and similarly for controls.
Primary end points measured the MRI-related complication-free
rate for safety and compared pacing capture threshold between MRI
and control subjects for effectiveness.The Advisa MRI System Study was funded byMedtronic. The following
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after MRI in subjects undergoing MRI (n ¼ 148). Differences
in pacing capture threshold values from pre-MRI to 1-month
post-MRI were minimal and similar between the MRI and control
groups.
CONCLUSIONS This randomized trial demonstrates that the
Advisa MRI pulse generator and CapSureFix MRI 5086MRI lead
system is safe and effective in the 1.5 T MRI environment without
positioning restrictions for MRI scans or limitations of body parts
scanned.
KEYWORDS Advisa MRI; CapSureFix MRI; Chest scan; EnRhythm
MRI; Magnetic resonance imaging; Pacemaker; Revo MRI; Safety;
SureScan; 5086MRI
ABBREVIATIONS AEAC ¼ adverse events adjudication committee;
MR ¼ magnetic resonance; MRI ¼ magnetic resonance imaging;
PCT ¼ pacing capture threshold; RF ¼ radiofrequency; SAR ¼
specific absorption rate
(Heart Rhythm 2013;10:685–691) I 2013 Heart Rhythm Society.
All rights reserved.Introduction
Safe, unrestricted whole body imaging, particularly
of the thoracic region, is a critical unmet need for
patients with pacemakers
Before the Food and Drug Administration approval of the
Medtronic Revo MRI system, all pacemakers had a labelwarning against magnetic resonance imaging (MRI) scan-
ning. The Revo MRI system has positioning restrictions for
MRI scans around the chest region; the position of the
isocenter of the radiofrequency (RF) transmitter coil must be
above the C1 vertebra or below T12. This may pose a
challenge to readily image thoracic structures optimally
without degrading the resolution of the image.
Cardiac magnetic resonance (CMR) defines cardiac
masses,1 detects ischemia,2 helps manage heart failure,3
defines coronary flow reserve,4 optimizes placement of
cardiac resynchronization therapy leads,5 and helps guide
RF ablation therapy through the integration of MRI into
clinical mapping systems.6 CMR is being integrated whole-
sale into ablation/imaging suites.7http://dx.doi.org/10.1016/j.hrthm.2013.01.022
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repeatable imaging defining a broad spectrum of cardio-
vascular pathologies coexisting within the same patient (with
pacemaker). Without the development of pacing systems
capable of easily and safely undergoing chest scans without
positioning restrictions, many patients with cardiovascular
diseases who would benefit most from MR scanning would
be excluded.Risks associated with MRI of patients with
pacemakers
MRI of pacing systems not labeled MR conditional remains a
cause of concern. Complications appear to occur at a
frequency of o10%,8 and while some are rare9 and clin-
ically benign without a permanent impact, others are
serious10 and potentially life-threatening.11 Underreporting
of the ill effects of off-label scanning is probably common. In
addition, when an adverse outcome occurs, litigation may
follow,12 further shrouding the details of the event.
Patient deaths during inadvertent scans or when patients
were insufficiently monitored have been documented.13–15
Despite an infrequent occurrence, the seemingly occasional
random occurrence of life-threatening asystole11 or ventric-
ular fibrillation15 may not provide satisfactory comfort for
the device patient or physician contemplating MRI if
technology exists that anticipates and addresses the risks
involved in scanning patients with pacemakers. Within this
context, the Advisa MRI pacemaker and CapSureFix
5086MRI lead system was developed to provide a safe,
reliable access to MRI at 1.5 T without anatomical position-
ing restrictions.Methods
Pacemaker system
Before the introduction of the Advisa MRI system for human
use, preclinical testing involving bench and animal inves-
tigations as well as computer modeling was conducted to
understand the effects of MRI on pacing systems.16 Multiple
system design modifications were required to ameliorate the
adverse interactions seen in these investigations: (1) the leads
were modified to reduce RF heating, (2) internal circuitry
was designed to reduce the potential for inappropriate
cardiac stimulation, (3) the amount of ferromagnetic materi-
als was limited, (4) a robust front-end protection network and
hybrid filtering was implemented to prevent disruption of the
internal power supply and mitigate the effects of MRI energy
coupling to the telemetry coil, (5) the reed switch was
replaced with a Hall sensor (disengaged during the MRI
SureScan mode) helping to provide predicable pacing during
MRI, and (6) a dedicated programming care pathway was
implemented to facilitate execution of a pre-MRI checklist
and selection of tailored pacing settings appropriate for the
patient during MRI. These modifications combine to effec-
tively address the risks of MRI scanning in patients with
pacemakers.Trial design and patient selection
This was a prospective randomized controlled, nonblinded,
multicenter trial (ClinicalTrials.gov Identifier NCT01110915).
The Declaration of Helsinki was followed, as well as laws and
regulations of participating countries. The institutional review
board approval and patient informed consent were obtained.
Enrollment required class I or II dual-chamber pacemaker
indications17 and pectoral implant. Patients agreed to undergo
a protocol-required MRI without intravenous sedation, had no
implanted non-MRI compatible devices or materials, had no
other implantable-active medical devices, and had no aban-
doned leads. Assuming the actual atrial or ventricular pacing
capture threshold (PCT) success rates were 96% in both the
MRI and control groups, sample sizes of approximately 133
MRI and 67 control subjects would achieve 90% power to
detect a 10% noninferiority margin difference by using the 1-
sided Farrington and Manning method. The overall sample
size was increased to 270 subjects to account for up to 25%
attrition from enrollment to 1-month post-MRI to ensure 200
subjects would have primary end point data.
Randomization
After successful device implant, randomization took place in
a 2:1 ratio to undergo (MRI group) or to not undergo (control
group) an MRI scan 9–12 weeks after implant. Statisticians
created randomization schedules stratified by center by using
randomized block methods. The center-specific random-
ization schedule was transferred in sequence to labels in
individually sealed envelopes, which were then opened
in order.
Data collection and analysis
Follow-up occurred 2 months postimplant, 9–12 weeks
postimplant, 1-week post-MRI/control, 1-month post-MRI/
control, 6 months postimplant, and then every 6 months until
study closure. The 9–12-week visit consisted of an evalua-
tion immediately before MRI (pre-MRI evaluation), during
MRI, and immediately after MRI (post-MRI evaluation), as
well as at corresponding time points for the control group.
During these evaluations, PCT at a pulse width of 0.5 ms,
sensed electrocardiogram amplitude, and lead impedance
were collected. Adverse events and technical observations
were evaluated at all visits, including before and after the
MRI scan. Pacemaker stored data, rhythm strips during PCT
testing, and case report forms were collected.
MRI
The MRI scans were performed with 1.5 T systems from 3
commercially available MRI manufacturers (General Elec-
tric, Philips, and Siemens). MRI sequences were chosen to
represent clinically relevant scans that were similar between
scanners. Sixteen MRI head and chest scan sequences were
performed. The scan protocol included MR scans with
maximized RF energy deposition up to specific absorption
rate (SAR) levels of 2 W/kg body and scans with maximized
gradient slew rates. The body coil served as the RF transmit
687Gimbel et al Advisa MRI System Randomized Clinical Study Resultscoil. Static magnetic field exposure was approximately 60
minutes with cumulative actual MRI scan times of approx-
imately 30 minutes (gradient and RF field exposure). Pulse
oximetry, verbal communication, and either electrocardio-
graphy or noninvasive blood pressure measurements pro-
vided monitoring information.Statistical analysis
The study had 2 primary objectives. An a-level of .025 was
used for each analysis.
The primary safety objective was to demonstrate that the
MRI-related complication-free rate in the month following
MRI was490%. A 1-sided, 1-proportion binomial exact
test was used, and the corresponding 1-sided 97.5% lower
confidence bound was calculated.
The primary effectiveness objective was to demonstrate
the noninferiority of the MRI group compared to the control
group with regard to the proportion of patients who
experienced a change in atrial or ventricular PCTr0.5 V
at 0.5 ms pulse width from before the MRI/control visit to theFigure 1 CONSORT19 diagram: pacing capture threshold population analysi1-month after the visit. The noninferiority margin was 10%.
A Farrington-Manning test of 2 independent proportions was
performed, and the 1-sided P value was used to evaluate the
test. Atrial and ventricular end points were evaluated
separately.
Data imputation methodology was prespecified in the
protocol. If a PCT measurement before the MRI/control visit
was unavailable or invalid, a valid 2-month PCT value was
used. For the post-MRI/control PCT value, the 1-month post
MRI PCT was used. If that did not exist or was not valid, the
first available follow-up value from (in order) 1-week post-
MRI, 6 months postimplant, or 12 months postimplant
was used.
Prespecified analysis exclusions were listed in the proto-
col. To assess the robustness of the analysis to missing/
excluded data, a tipping point analysis was performed on the
basis of all randomized patients. A tipping point analysis
replaces the missing data with values so that the resulting P
value is equal to (or greater than but close to) a prespecified
significance level.18 Tipping point analyses were carried out
separately for atrial and ventricular end points.s. MRI ¼ magnetic resonance imaging; PCT ¼ pacing capture threshold.
Table 1 Baseline demographic and clinical characteristics
Characteristic
MRI group
(n ¼ 177)
Control group
(n ¼ 86)
Age (y) 68.1  12.8 68.7  10.8
Sex: Male 109 (61.6%) 54 (62.8%)
Race
White or Caucasian 147 (83.1%) 75 (87.2%)
Asian 4 (2.3%) 2 (2.3%)
Black or African American 3 (1.7%) 0 (0.0%)
Hispanic or Latino 2 (1.1%) 0 (0.0%)
American Indian or Alaska Native 1 (0.6%) 0 (0.0%)
Not available 20 (11.3%) 9 (10.5%)
Primary indication for implant
AV block 51 (28.8%) 35 (40.7%)
Sinus node dysfunction 95 (53.7%) 41 (47.7%)
Other 31 (17.5%) 10 (11.6%)
Atrial arrhythmias 119 (67.2%) 57 (66.3%)
Ventricular arrhythmias* 23 (13.0%) 8 (9.3%)
AV junctional arrhythmias and blocks 108 (61.0%) 50 (58.1%)
Cardiovascular surgery history
Ablation 9 (5.1%) 5 (5.8%)
Coronary artery bypass graft 15 (8.5% 5 (5.8%)
Coronary artery intervention 23 (13.0%) 7 (8.1%)
Valve surgery 16 (9.0%) 5 (5.8%)
Cardiovascular history
Cardiomyopathy 30 (16.9%) 8 (9.3%)
Myocardial infarction 17 (9.6%) 9 (10.5%)
Syncope 70 (39.5%) 35 (40.7%)
Valve dysfunction 38 (21.5%) 21 (24.4%)
Values are represented as mean  SD or as n (%).
AV ¼ atrioventricular.
*Ventricular arrhythmia includes long Q/T syndrome, premature ventricular
complexes, nonsustained ventricular tachycardia, ectopic ventricular beats,
slow ventricular rhythm, polytop ventricular extrasystoles, ventricular extra
systoles, torsades de pointes, and severe left diastolic dysfunction.
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the 1-month post-MRI visit was compared to a value of 80%
by using Kaplan-Meier method with a 95% lower confidence
bound. Events between studies were compared by using the
Fisher exact test.
Adverse event classification
Adverse events were collected throughout the trial. The
adverse events adjudication committee (AEAC) reviewed all
events, providing adjudication of the relationship between
adverse events and the implant procedure, MR procedure,
and the pacing system. On occasion, adverse events were
classified as having an unknown relationship. All adverse
events were classified as either a complication or an
observation. Complications included events resulting in
death, involving termination of significant device function,
or required invasive intervention; an observation was any
adverse event that was not a complication.
The accreditations for all MR scanners were reviewed.
The scan sequences, duration, and SAR values for all
subjects were reviewed by at least 3 members of the scan
advisory board.
Results
Trial population sample size
Distribution of patient enrollments, randomization group,
and inclusion and exclusion of data is presented in Figure 1.
Mean follow-up was 7.1  4.1 months (range 0–18.8
months) for the 269 subjects enrolled between June 2010
and October 2011. Evaluation of the Advisa MRI system
included 1903.1 months of the device implant in 263
successfully implanted subjects. Patient characteristics of
the patients with pacemakers are shown in Table 1.
Safety
A total of 150 subjects underwent an MRI scan, and 148 of
these were followed through the 1-month post-MRI visit or
later follow-up and were included in the analysis. One
subject missed the 1-month post-MRI visit and 1 died before
the 1-month post-MRI visit. Neither subject experienced an
MRI-related complication.
There were no MRI-related complications among the 148
patients included in the analysis. This is 100% success (1-
sided lower 97.5% confidence bound 97.5%). The primary
safety objective was met (Po .0001).
While there were no MRI-related complications, the
AEAC classified 5 events as MRI-procedure-related obser-
vations. Subjects reported implant site paresthesia (n ¼ 2)
and implant site warmth (n ¼ 1), which required no actions
and the MRI scanning continued. Two subjects had their
MRI scans stopped early owing to a hot flush (n ¼ 1) and
implant site pain (n ¼ 1). Diagnostic tests and procedures
were unremarkable for all 5 subjects.
Three deaths occurred: 2 in the MRI group and 1 in the
control group. None were related to the Advisa MRI
system, implant procedure, or MRI procedure asadjudicated by the AEAC. Of the 2 MRI group deaths, 1
subject died of sudden cardiac death 21 days post-MRI and
the other died 26 days postimplant without having an
MRI scan.
The proportion of subjects free of pacing system-related
complications through 4 months postimplant was 92.3%
with a 1-sided lower 95% confidence bound of 89.1%.
Twenty-five pacing system-related complications were
reported from 20 subjects. System-related complications
with an occurrence greater than 1 included lead dislodge-
ment, pericardial effusion, and cardiac perforation (Table 2).
The percentages of patients with these events were not
statistically different from those seen in the EnRhythm MRI
study.20Effectiveness
No patients saw an increase of40.5 V in their atrial PCT,
and so the success rate for atrial PCT was 100% (141 of 141)
in the MRI group and 100% (75 of 75) in the control group
(Figure 2). With both rates at 100%, a P value could not be
calculated.
The success rate for ventricular PCT was 98.0% (146 of
149) in the MRI group and 97.5% (78 of 80) in the control
group (Figure 3). The 95% confidence interval for the
Table 2 System-related complications occurring more than once in both the Advisa MRI and the EnRhythm MRI studies through 4 months
postimplant
EnRhythm MRI (n ¼ 467) Advisa MRI (n ¼ 266)
Events No. of events No. of subjects No. of events No. of subjects P
Lead dislodgement 17 17 (3.6%) 14 11 (4.1%) .84
Cardiac perforation 2 2 (0.4%) 3 3 (1.1%) .36
Pericardial effusion 3 3 (0.6%) 2 2 (0.8%) 1.00
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test evaluating whether the MRI group is noninferior to the
control group with a 10% margin was o.0001.
A number of randomized patients (atrial PCT: 20% MRI
and 13% control subjects; ventricular PCT: 16% MRI and 7%
control subjects) did not contribute data to the analysis
primarily because of MRI scans not being performed for
various reasons and atrial arrhythmia (Figure 1). Tipping point
analyses were done to assess potential effects of the missing
data. Those analyses showed that unless the missing patients
had results far off the observed results (ie, 10 of 36 and 10 of
28MRI group patients with missing data would need to see an
atrial and ventricular PCT rise of40.5 V post-MRI, respec-
tively), the study would still meet its end points.
One subject in the MRI group experienced a change of
1.75 V from the pre-MRI visit to the 1-month post-MRI visit.
A review of thresholds and recorded pulse generator data for
visits pre- and post-MRI scan indicate that this subject
experienced high thresholds shortly after implant, which
continued to increase over time. Thresholds reported pre-
MRI and immediately post-MRI examination were the same
(2 V at 0.5 ms), indicating that MRI had no effect on the
subjects’ PCT. This subject had a system revision 185 days
post-MRI for lead dislodgement. The lead dislodgment was
adjudicated as not MRI procedure related.Discussion
This prospective randomized controlled, nonblinded, multi-
center trial was conducted to evaluate the safety and efficacy
of a specially engineered full featured pacing system
designed to undergo 1.5 T MRI of any body part and without
anatomical positioning restrictions. This is the first2%
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Figure 2 Atrial pacing capture threshold changes from the pre-9–12-wprospective randomized evaluation known of patients with
pacemakers who were receiving MRI scans within the
cardiac region. Radiology conditions are simplified by
removing positioning restrictions and thus facilitate diag-
nostic MR scanning. The primary objectives of safety and
efficacy were robustly demonstrated. There were no MRI-
related complications observed in this study, supporting the
view that the Advisa MRI SureScan technology effectively
addresses the many and varied potential concerns that
physicians consider and patients with pacemakers face when
undergoing 1.5 T MRI. System-related complications asso-
ciated with system use (Table 2) were within an acceptable
and expected range.21Comparison to off-label use of conventional
unmodified pacing systems
Many adverse effects reported during off-label MRI are
infrequent. Nevertheless, this may not allay the concerns of
the everyday practitioner who might want to regularly scan
patients with pacemakers. Strategies to facilitate off-label
scanning have been proposed.22–24 However, without a
system specifically designed and modified for safe scanning,
these strategies do little or nothing to address lead heating,
power on reset and its consequences, unpredictable reed
switch behavior, and inhibition of device output, for exam-
ple. In contrast, because of the many system modifications,
the Advisa MRI system provides a safe predictable MRI
experience for both the patient and the physician as
confirmed in this study.
Suggestions that off-label MRI is “safe” for patients with
pacemakers remain causes of concern, particularly since
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Figure 3 Ventricular pacing capture threshold changes from the pre-9–12-week visit to the 4-month visit. MRI ¼ magnetic resonance imaging.
Heart Rhythm, Vol 10, No 5, May 2013690MRI. Why? Perhaps most importantly, previous studies
involving off-label scanning are characterized by very small
numbers of specific devices (often less than 3 and often only
1).25 Different pulse generators and lead pairings are
presented, making it difficult to compare “apples to apples”
when evaluating the safety of off-label scanning of any
specific device and lead system. The argument that off-label
scanning of devices is potentially safe (or even that the risks
are acceptably manageable)26 is significantly undermined by
the statistically small sample of each device and lead system
presented in previous literature.25 In contradistinction, the
Advisa MRI trial presented is statistically powered to
demonstrate the safety and efficacy of its prespecified end
points of a specific single system (pulse generator and leads)
undergoing 1.5 T MRI.
The off-label scanning of patients dependent on pace-
makers is “strongly discouraged.”22 Patients dependent on
pacemakers are most vulnerable to the effects of unexpected
and unpredictable power on reset because these events may
result in asystole.11 Significantly, the system modifications
and programming modalities available in the Advisa MRI
system allow patients dependent on pacemakers to enjoy
safe, reliable access to MRI.
The evaluation of the Advisa MRI system showed no
evidence of PCT changes, power on reset, or unintended
cardiac stimulation. Importantly, this study gives patients
with Advisa MRI access to the full range of imaging
capabilities that MRI can offer, including directly imaging
all cardiac structures.
Limitations
Only 1.5 T MRI was evaluated. Only 1 type of pulse
generator (Advisa MRI) and 1 type of lead (5086MRI) in a
dual-chamber configuration was evaluated. The labeling
restrictions for the Advisa MRI SureScan pacemaker system
require keeping the SAR at or below 2 W/kg. From a
practical perspective, other publications describing MRI of
patients with device where SARwas limited to less than 2W/
kg (for safety reasons to reduce heating) failed to mention
any compromise of image quality in the MR scans obtained.
In fact, in multiple studies, “diagnostic quality” studies23 arethe rule, not the exception, with investigators reporting that
despite limiting SAR below 2 W/kg “all clinically relevant
MRI sequences necessary for diagnosis were performed.”27
In addition, pacemaker dependency was not collected, nor
was information regarding the patient’s left ventricular
ejection fraction.Conclusions
This prospective randomized trial demonstrates that the
Advisa MRI system is safe and effective in the 1.5 T MRI
environment, providing MRI access without compromising
positioning restrictions.References
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